Placental tissue injury is concomitant with tumor development. We investigated tumor-driven placental damage by tracing certain steps of the protein synthesis and degradation pathways under leucine-rich diet supplementation in MAC16 tumor-bearing mice. Cell signaling and ubiquitin-proteasome pathways were assessed in the placental tissues of pregnant mice, which were distributed into three groups on a control diet (pregnant control, tumor-bearing pregnant, and pregnant injected with MAC-ascitic fluid) and three other groups on a leucine-rich diet (pregnant, tumor-bearing pregnant, and pregnant injected with MAC-ascitic fluid). MAC tumor growth downregulated the cell-signaling pathways of the placental tissue and decreased the levels of IRS-1, Akt/PKB, Erk/MAPK, mTOR, p70S6K, STAT3, and STAT6 phosphorylated proteins, as assessed by the multiplex Millipore Luminex assay. Leucine supplementation maintained the levels of these proteins within the established cell-signaling pathways. In the tumor-bearing group (MAC) only, the placental tissue showed increased PC5 mRNA expression, as assessed by quantitative RT-PCR, decreased 19S and 20S protein expression, as assessed by Western blot analysis, and decreased placental tyrosine levels, likely reflecting upregulation of the ubiquitin-proteasome pathway. Similar effects were found in the pregnant injected with MAC-ascitic fluid group, confirming that the effects of the tumor were mimicked by MAC-ascitic fluid injection. Although tumor progression occurred, the degradation pathway-related protein levels were modulated under leucine-supplementation conditions. In conclusion, tumor evolution reduced the protein expression of the cell-signaling pathway associated with elevated protein degradation, thereby jeopardizing placental activity. Under the leucine-rich diet, the impact of cancer on placental function could be minimized by improving the cell-signaling activity and reducing the proteolytic process.
INTRODUCTION
Cancer cachexia is a common syndrome in cancer patients, leading to weight loss and decreasing muscle and adipose tissue mass in particular [1] . The ubiquitin-proteasomedependent pathway is one of the major proteolytic systems leading to skeletal muscle waste [2] . Increased proteolysis is responsible for the catabolic response in several tumor-bearing animal models [3] and in some cancer patients [4] [5] [6] [7] , although decreased protein synthesis also contributes to muscle wasting.
Despite the low incidence of tumors in pregnant mothers, some studies have shown that there is approximately one per 1000 pregnancies. Recently, studies have shown that the incidence and outcomes of pregnancy-associated cancer are increasing [8] [9] [10] [11] [12] . Studies regarding pregnancy-associated cancer are of great clinical interest because pregnancyassociated cancer affects the health of both the mother and the fetus. Cancer during pregnancy may result in impaired fetal and placental growth or even in metabolic changes in both the mother and the fetus, mainly as a result of nutritional competition between the fetus and the tumor and/or as a result of cytokines and factors released from the tumor and/or host cells [13] [14] [15] [16] .
Indeed, placental function is essential for normal fetal development and growth. Certain stress situations such as protein restriction and some diseases, including cancer, can jeopardize the function of the placenta and often lead to intrauterine growth restriction (IUGR), as shown by our previous findings [17] [18] [19] . The activity of placental amino acid transporters is decreased in IUGR. Inhibition of the mechanistic target of the rapamycin (mTOR)-signaling pathway has been shown to decrease the activity of a specific amino acid transporter system (system L) in human placental villous fragments, and placental mTOR activity is decreased in IUGR [20] . It has been well-established that a variety of factors affect the fetus in the intrauterine environment and can affect its development into a healthy adult, eventually contributing to the development of a number of adult diseases such as diabetes [20, 21] .
Overall, protein synthesis in the placental tissue is essential for normal function and fetal development, such as providing an immunological barrier between the mother and fetus, secreting and releasing hormones and cytokines, and transferring all of the necessary nutrients and metabolites for healthy fetal growth [20] . The largest studies on pathways involving protein synthesis have related to the mTOR-signaling pathway. The serine-threonine kinase mTOR is an important regulator of protein synthesis and plays important roles in other biological processes that support cell growth and survival.
Leucine is one of the branched-chain amino acids that plays an important role in skeletal muscle metabolism that appears to be unique to this amino acid and leads to improved protein synthesis and decreased proteolysis [13, 14, [22] [23] [24] . Leucine regulates protein synthesis in skeletal muscles following food intake, stimulating the mTOR pathway and inhibiting the ubiquitin-proteasome pathway. A leucine-rich diet can improve carcass nitrogen levels and lean body mass in both Walker 256 tumor-bearing rats and MAC16 adenocarcinoma-bearing mice [1, [24] [25] [26] [27] [28] . Both of these tumors are experimental models of cachexia [29] ; for this reason, we chose to use the MAC16 tumor in this work to investigate the metabolic and biochemical changes associated with pregnancy in order to characterize these effects. Maternal nutrients such as glucose and amino acids are provided during fetal growth through the placenta to favor fetal development. Nevertheless, during pregnancyassociated cancer, these maternal nutrients can be diverted to promote tumor growth, thereby impairing fetal growth and stimulating muscle wasting in the host [22] . With an understanding of the effects of leucine on cell signaling, we herein investigated the effects of tumor growth and of the products released by the tumor and/or host in the ascitic fluid on placental cell signaling and degradation under leucine-rich diet. We hoped to establish whether this nutritional supplementation was able to improve placental metabolism.
MATERIALS AND METHODS

Animals
Forty-eight female NMRI mice (;60-to 90-days-old) were obtained from the animal facilities of the State University of Campinas (UN-ICAMP). The females were matched with adult males overnight (four females:one male) as described by the harem method [30] . The first day of pregnancy was determined based on detection of sperm in the vaginal smear and the presence of a vaginal plug. All the pregnant mice were maintained in collective cages with free access to water and food under standard conditions (228C 6 28C, 12L:12D). Semipurified diets were used in accordance with the American Institute of Nutrition (AIN-93) [31] . The normoprotein control diet consisted of 18% protein (casein was the sole source of protein, which contained 1.6% Lleucine). The leucine-rich diet contained 18% protein and an additional 3% Lleucine [32] (for humans, this dosage corresponds to an intake of ;2 g leucine per day). Both diets contained similar amounts of nitrogen (;13.2 mg N 2 /100 g diet). The control diet contained 20% casein, carbohydrate (39.7% cornstarch, 13.2% dextrin, and 10% sugar), fat (7% soy oil), fiber (5% cellulose microfiber), salt mix (3.5%), and vitamin mix (1.0%) and was complemented with 0.3% cystine and 0.25% choline. The amino acids in the leucine-rich diet were adjusted to reduce the equivalent amount of carbohydrates required to maintain isocaloric diets; the other ingredients-fat, fiber, salt, and vitamin mix as well as cystine and choline-were the same as in the normoprotein diet. The composition of these diets has been previously published [31] [32] [33] . The Lleucine and cornstarch were kindly provided by Ajinomoto Brasil and Corn Products, respectively.
The pregnant mice were randomly allocated into six groups. Three groups were fed the control diet, that is, C, pregnant control, MAC, tumor-bearing pregnant, and A, pregnant injected with ascitic fluid, and three other groups were fed with the leucine-rich diet, that is, L, pregnant, LMAC, tumor-bearing pregnant, and LA, pregnant injected with ascitic fluid.
Tumor Implant and Ascitic Fluid Injection
The MAC16 colon adenocarcinoma, originally donated by Professor Michael J. Tisdale (Aston University, England), has been maintained in our laboratory under liquid nitrogen and through consecutive subcutaneous or intraperitoneally passages. The mice assigned to the tumor-bearing groups, MAC and LMAC, received a subcutaneous injection of MAC16 tumor cells (;1 3 10 6 viable cells in 0.2 ml of saline solution) in the right flank after the confirmation of pregnancy. The ascitic fluid obtained from the intraperitoneal cavity of MAC16-tumor-bearing mice was centrifuged at 10 000 3 g for 10 min to remove the neoplastic cells; this fluid contains most of the products released from the tumor and/or host cells as previously reported in our studies [33, 34] . Groups A and LA received daily intraperitoneal injections of 0.2 ml ascitic fluid until the 19th day of pregnancy. All the groups were monitored for 19 days after tumor implantation. The general UK Coordinating Committee for Cancer Research [35] guidelines for animal welfare were followed, and the institutional committee approved the protocols for Ethics in Animal Research (CEEA/IB/UNICAMP, protocol 1925-1).
The pregnant mice were killed by cervical dislocation 19 days after tumor implantation, which corresponded to the 20th day of pregnancy, and the fetuses and placentas were removed and weighed. The tissues were maintained at À808C until analysis.
Placental Protein Assay
Part of the placental tissue was homogenized in protein extraction buffer (20 mM HEPES, 100 mM KCl, 0.2 mM ethylenediaminetetraacetic acid, 2 mM ethylene glycol tetraacetic acid, 1 mM dithiothreitol, 50 mM NaF, 1 mM 3,3 0 -diaminobenzide tetrahydrochloride, 0.5 mM orthovanadate, and 50 mM glycine, pH 7.4) followed by centrifugation at 10 000 3 g for 15 min at 48C. The supernatant was analyzed for total protein content using the Bradford assay, which measures proteins by their binding capacities to Coomassie Brilliant Blue reagent at 595 nm [36] . Protein degradation was determined indirectly by measuring the nanomoles of tyrosine content per microgram of placental protein based on the fluorometric assay described by Waalkes and Udenfriend [37] . We have previously shown that the tissue tyrosine content is inversely proportional to the amount of tyrosine released into the medium in the tissue perfusion assay (data not shown) [38] .
Cell-Signaling Pathway
We evaluated the cell-signaling pathway by tracing the following phosphorylated protein expressions: pIRS- . Protein expressions were measured using a specific multiplex kit from Millipore Luminex 200TM (Luminex Corporation) following the manufacturer's technical procedures.
Western Blot Analysis
Placental homogenized samples (as described below) were separated by 12% SDS PAGE electrophoresis under reducing conditions. After gel electrophoresis and the transfer of proteins to a nitrocellulose membrane, the proteins were blocked at room temperature for 1 h in 5% nonfat dry milk and incubated overnight at 48C with antibodies against the 20S proteasome subunit and the 19S MSSI ATPase regulator subunit (both diluted 1:1500; Enzo Life Science). Immunoreactivity was detected by the sequential incubation of membranes with rat anti-mouse secondary antibody for 1 h at room temperature, which was visualized using a chemiluminescence detection system. The 19S and 20S protein levels were estimated relative to the constant level of tubulin, a 55-kDa protein. 
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0 a n d r e v e r s e p r i m e r 5 0 GTTAGCAGATGGACAGGTTTGG3 0 ). To confirm the integrity of the extracted RNA, transcription of the housekeeping gene b-actin (GenBank accession no. XM_508298.2) was analyzed as a control.
Complementary DNA was produced using a high-capacity cDNA reverse transcription kit (Applied Biosystems) containing MultiScribe Reverse Transcriptase. Complementary DNA synthesis was performed on 3 lg of RNA at 428C. Finally, cDNA was diluted 1:2 prior to its use in quantitative PCR.
PCR was performed in a Step One Plus System (Applied Biosystems) in 96-well microtiter plates using a final volume of 20 ll. Optimum reaction conditions were obtained with 10 ll of Fast SYBR Green Master Mix (Applied Biosystems) containing Fast SYBR Green Master Mix 23, forward and reverse primers (5 nM), cDNA template, and water. Finally, 4 ll template cDNA (5 ng/ ll) was added to the reaction mixture. The samples were denatured at 958C for 10 min, followed by 40 PCR cycles at of 10 sec at 958C, 7 sec at 608C, and 12 sec at 728C; and melting curve of 63-958C with a slope of 0.1 C/sec. PCR amplification was performed in triplicate. The purity of the amplified PCR products was verified with melting curves. All the data were analyzed with 7500 software (Applied Biosystems), and the values are expressed as the relative expressions with respect to the control levels (2 ÀDDCt ).
Statistical Analysis
Data are expressed as the means 6 SD. Data were statistically analyzed by one-way ANOVA [39] followed by the Bonferroni test for comparisons among groups (GraphPad Prism software, version 5.0). P values less than 5% were considered to be statistically significant.
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RESULTS
Effects Induced by MAC16 Tumor-Bearing Mice on Placental and Fetal Morphometric Parameters
The data showed a negative correlation between tumor growth and fetal health. As we published previously, even though there was no difference in the number of fetuses per dam across the groups, we observed that the ratio between the number of resorptions per number of fetuses was significantly elevated in the MAC group in comparison to the LMAC group, which showed a lower level of fetal resorption (Table 1) . Moreover, the percentage of fetal weight decreased in the MAC and A groups compared to the C group. On the other hand, the animals in the L group developed an increase in the percentage of fetal weight compared to C; this percentage also increased in the LMAC group in relation to the MAC group (Table 1) . However, no significant difference among the groups was detected in the placental protein content or in the ratio of placental weight to fetal weight. The percentage of placental weight was decreased only in the MAC group (Table 1) .
Tumor Growth Led to Changes in Cell Signaling that Were Modulated by Leucine Supplementation
Tumor growth promoted a down-regulation in the cellsignaling pathway in placental tissues. We detected a strong association between bearing a tumor and demonstrating a decreased protein expression that affects the MAPK/ERK-and PI3K/Akt/mTOR-signaling pathways. Figure 1 shows that the expression of the phosphorylated/activated forms of IRS-1, Akt, Erk, mTOR, STAT3, and STAT6 were decreased in MAC group. Additionally, some of these proteins, such as Erk and mTOR, had a decreased activation level in the A group. Leucine supplementation, under our experimental conditions, had no significant stimulating effect on the MAPK/ERK-and PI3K/Akt/mTOR-signaling pathways because no difference was found between the C and L groups. On the other hand, leucine supplementation led to an important modulation preventing any decrease in the LMAC group, whereas the PI3K/Akt/mTOR-signaling pathway remained similar to that in the L group (Fig. 1) .
MAC16 Tumor Growth and Leucine Supplementation Increase PC5 Expression
To evaluate the influence of tumor growth and the effects of leucine supplementation on the degradation pathway, we analyzed the tyrosine content, which showed a deep decrease in the MAC and A groups (approximately 15% in MAC and 40% in A) in comparison to the C group. In our previous data, the tyrosine content was inversely proportional to the tyrosine release, indicating protein degradation [23, 27, 32] . Conversely, all of the leucine groups had decreased tyrosine contents when compared to the control group, although no difference was found among the leucine groups (Table 1 ). PC5 and PC2 gene expression and 20S and 19S protein expression are involved in the ubiquitin-proteasome pathway. Figure 2 shows that the PC5 gene expression is increased in the MAC, LMAC, and LA groups when compared with the C group; however, no difference in PC2 gene expression was found in tumor-bearing mice compared to the respective controls (C and L) (Fig. 2) . These genes are responsible for the proteolytic core expression in the proteasome subunit, which regulates the cleavage of proteins by this proteolytic mechanism [40, 41] . The proteolytic proteins, 20S and 19S, were increasingly expressed in the placental tissue, but only in the placenta of the MAC group (Fig. 2) . On the other hand, the LMAC group showed no increase in proteolytic protein expression (Fig. 2) .
DISCUSSION
In this study, we highlighted the nutritional importance of a leucine-rich diet in modulating the damaging effects induced by tumor growth on placental protein expression related to the protein-signaling pathway in MAC16 tumor-bearing mice. Our data suggest that tumor-induced fetal resorption and decreased fetal weight could be related to damage within the placental metabolism, which may be caused by elevated expression of placental genes of the degradation pathway and appear to be associated with decreased expression of some key proteins related to the mTOR pathway. The relevant physiological benefits of nutritional supplementation with leucine are important to the maintenance of placental cell signaling, which is associated with the similar levels of protein expression as those in the ubiquitin-proteasome pathway, even in presence of tumor growth. Such expression prevents spikes in fetal resorption and thereby improves the fetal weight in these dams (LMAC and LA).
During pregnancy, fetal growth and development depend on normal placental function. It has been well-established that maternal food restrictions such as protein restriction affect the placenta as well as fetal growth and lead to IUGR [42, 43] . Protein synthesis pathways are most likely affected during IURG because down-regulation of the mTOR pathway would decrease the level of cell growth and activity [20, 21, 44, 45] . Similarly, fetuses from the MAC group had a lower weight and demonstrated resorption process, both of which could be related to decreases in placental cell growth and activity resulting from down-regulation of the MAPK/ERK-and PI3K/ Akt/mTOR-signaling pathways [20] . We also assessed the placental cell-signaling pathways through the measurement of phosphorylated/active proteins such as IRS-1, Jnk, STAT3, and STAT6. We observed low activity in most of these proteins, 99.6 6 4.5 108.7 6 1.5 Placenta tyrosine content (nmol/lg protein) 114.1 6 11.7 97.8 6 6.1* 70.5 6 2.9*** 67.4 6 2.9*** 75 6 3.9* 69.0 6 0.2*** a Data are expressed as the means 6 SD. Some results were calculated and expressed as percentages, corresponding to our previous published data, Viana and Gomes-Marcondes [33] . *P , 0.05, ***P , 0.001 for comparison with the C group. P , 0.05 for comparison with the MAC group. VIANA AND GOMES-MARCONDES except for Jnk expression, in the MAC group. These data are compatible with our results, which show that fetal impairment, including low weight and high fetal resorption, was strongly related to placental damage in the MAC group. Additionally, the current data indicate that the observed fetal impairment happened as a result of a nutritional supply failure because the placental tissue was damaged not only by the tumor's effects, which diverted the nutritional supply and energy from the fetus, but also by the factors produced by tumor and/or host cells that were found in the ascitic fluid, as verified in the A group. Previous reports have provided evidence for the presence of these factors in the ascitic fluid and for their effective actions on protein degradation [18, 34, [46] [47] [48] . We isolated proteolysis-induced factor (PIF) from the MAC16 ascitic fluid, as previous reported by Todorov and colleagues [49] , and confirmed its strong effects on muscle protein synthesis and degradation [34, [49] [50] [51] . Similar results were found here where the A group exhibited impaired fetal weight and reduced placental weight as well as downregulation of pERK/MAPK, pIRS-1, and pmTOR protein expression. Because these proteins are related to the process of protein synthesis, we suggest that placental damage is directly affected by the inhibition of the placental anabolic processes initiated by the tumor and tumor factors [33, 34] .
LEUCINE-RICH DIET IMPROVES TUMOR-DAMAGED PLACENTA
On the other hand, many studies have shown that the principal effect of tumor growth in the host is to increase protein degradation [26, 47, 52] . As observed in our previous reports and in those from other researchers, the ubiquitinproteasome pathway in skeletal muscle is activated during cancer evolution, decreasing the protein content in response to the elevated release of tyrosine relative to the increased expression of 20S and other proteasomal subunits, ultimately leading to protein degradation [19, 23, 50, 53, 54] . Likewise, in response to tumor growth, the placental tissues had a higher protein expression of the 20S and 19S subunits, in line with an increase of protein catabolism. Moreover, PC2 and PC5 genes are related to the 20S proteasome subunit [40, 41, 48] , and their increased genetic expression is commonly found during skeletal muscle wasting [40, 41, 51] . In addition to this fact, we observed enhanced PC5 gene expression in the placenta tissues of the MAC16 tumor-bearing group. As mentioned above, the A group followed the MAC group in the variation they exhibited, including a tendency of increased PC5 gene expression (albeit, not statistically significant). In this case, the existence of other mechanisms leading to placental protein degradation likely explains the induction of lower fetal weight. Such an induction in the A group was associated with a reduction in the expression of the pERK/MAPK and pmTOR proteins. The fluid obtained from MAC16 tumor-bearing mice, LEUCINE-RICH DIET IMPROVES TUMOR-DAMAGED PLACENTA which was injected daily into the pregnant mice (A group), induced effects similar to those produced by the tumor growth, probably because tumor cells produce humoral factors, mainly PIF, that can be responsible for the protein wasting seen in placental tissues. PIF isolated from a cachexia-inducing murine tumor (MAC16) has been shown to cause muscle wasting in nontumor-bearing mice [55] as a result of the coordinated activation of the lysosomal, Ca 2þ -dependent and ubiquitinproteasome-dependent proteolytic systems [53, 54] .
Furthermore, leucine is considered to be the principal anabolic agent of an amino acid-signaling pathway that regulates protein synthesis [56, 57] . Several lines of evidence, including our previous reports, have demonstrated that leucine is the most effective amino acid for stimulating protein synthesis and decreasing catabolism in both in vivo and in vitro assays [23, 24, 27, 51, [58] [59] [60] .
In the present work, we observed that when animals consumed a leucine-rich diet certain parameters were changed and improved, reversing fetal weight loss when compared to both tumor-bearing groups (MAC and LMAC). Therefore, we found evidence of the benefits produced by leucine-rich dietary supplementation, not only in the placental tissue but also in the fetus: fetal weight was higher in the LMAC group and fetal resorption was lower in the LMAC compared to the MAC group, in agreement with our previous data [19, 33] . According to these data, the placenta cell-signaling pathway was unchanged by the leucine-rich diet even in the LMAC group compared to the C and L groups. These data show that, most likely, leucine protected these tissues (placenta and fetus) from the damaging effects produced by tumor growth, as observed in the MAC and A groups. On the other hand, the injection of ascitic fluid in the leucine-treated group (LA) also affected most of the parameters analyzed here in this work except for pIRS-1 and pmTOR cell-signaling proteins. In this case, we must investigate why these proteins were down-regulated in the LA group without any change in the placenta protein content, while in other cells, the proteins were associated with no impairment in the fetal parameters. We cannot exclude that leucine led to the up-regulation of certain proteolytic proteins, such as 20S, and of PC5 and PC2 gene expression in all leucine-treated groups (L, LMAC, and LA). Similar observations have also been published in previous reports about skeletal muscle, although the protein balance remained strongly positive and always higher in the group fed a leucine-rich diet than in the control.
In conclusion, tumor evolution increased fetal resorption, decreased fetal weight, and reduced placental cell activity, down-regulating the expression of proteins from the cellsignaling pathway and raising those from the degradation pathway (Fig. 3A) . On the other hand, leucine supplementation in tumor-bearing dams prevented fetal resorption, improved fetal weight, and maintained the expression of the placental cell-signaling proteins and of the proteasomal subunits 20S and 19S, thereby minimizing protein degradation despite the elevated PC5 levels in placental tissues (Fig. 3B) . New experiments are currently underway to better elucidate the improvement of the cell and host responses during tumor evolution under the modulatory influence of leucine-rich diet supplementation.
